People · Operator
Named in public records as an officer, director or promoter · active 2010–2011 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Afraxis, Inc. | — | Biotechnology | Seed | $2.9M | $13.3M | 2010 |
| Zacharon Pharmaceuticals Inc. | — | Pharmaceuticals | Pre-Seed | $500K | $23.7M | 2010 |
Court B. Turner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Court B. Turner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jay B. Lichter | 2 | 3 |
| Court Turner | 1 | 6 |
| Robin M Jackman | 1 | 2 |
| David B. Campbell | 1 | 1 |
| Steve B. Heinemann | 1 | 1 |
| Braden B. Bohrman | 1 | 1 |
| Braden Bohrman | 1 | 1 |
| Steve Heinemann | 1 | 1 |
| Doug Downs | 1 | 1 |
| Timothy B. Scott | 1 | 1 |
| Douglas J. Cowns | 1 | 1 |
| Steve B. Heinemann, Ph.D | 1 | 1 |
| Charles A. Glass | 1 | 1 |
| Braden B. Bohrmann | 1 | 1 |
| Doug B. Downs | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.